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Hepatitis E virus (HEV) infection is being increasingly recognized in
medical research as HEV infection has reached industrialized countries.
Although HEV was discovered in 1983 (Balayan et al., 1983) and
subsequent experimental analyses were initiated since 1990/1991 on
HEV isolates (Reyes et al., 1990), there exists a considerable lack of
understanding and knowledge of transmission routes, life-cycle,
pathogenesis, genome variability and viral evolution.
Substantial epidemics and sporadic outbreaks of hepatitis E occur in
tropical and sub-tropical countries (e.g., in India, Uganda, Sudan, and
Mexico), with up to tens of thousands affected (Dalton et al., 2013;
Kamar et al., 2012). Approximately two billion people (one-third of
the world population) live in areas endemic for HEV and are at risk
(Perez-Gracia et al., 2013). HEV infections are less frequently docu-
mented in industrialized countries, as it is believed to be associated
with travel to HEV-endemic countries. However, by the end of the mil-
lennium, the numbers of autochthone cases were rising exponentially.
HEV infections in Western Europe have been reported (Dalton et al.,
2013; Kamar et al., 2012; Pischke et al., 2014). Reasons for discrepancies
of HEV presentation between developing and developed countries are
diverse. The possible likelihood refers to the route of transmission and
the different distribution of HEV genotypes (Pauli et al., 2015; Sayed
et al., 2015). In developing countries, HEV infection is transmitted
mainly as waterborne/fecal-oral due to poor hygiene conditions,
whereas in developed countries HEV is transmitted mainly foodborne
due to zoonotic transmission by consumption of undercooked meat
and bowels (Mansuy et al., 2016). In this regard, HEV is unique, as the
only hepatitis virus with an animal reservoir.
HEV variants are viral factors that are known to be associated with
transmission dynamics and pathogenicity (Kamar et al., 2012, 2014a;
Lee et al., 2016; Meng, 2011). HEV mutations occur under selective
pressure imposed by the host immune system and by antivirals. HEV
heterogeneity shall contribute towards HEV physiology, pathogenesis
and transmission patterns (Lhomme et al., 2014a). In this review, we
aim to compile knowledge and discuss recent advances on the casual
role of HEV heterogeneity and its variants on viral morphogenesis,
pathogenesis, clinical relevance and antiviral resistance.
2. Clinical Course and Pathogenesis of HEV Infection
Although the majority of HEV infections are asymptomatic, the
clinical course of symptomatic infections includes acute and chronic
hepatitis E, fulminant liver failure and extrahepatic symptoms (Debing
et al., 2016a; Hoan et al., 2015). Acute hepatitis E is usually deﬁned as
a self-limiting disease and lasts approximately 8 weeks and the
symptoms are typically unspeciﬁc and mostly indistinguishable from
other types of acute viral hepatitis (Wedemeyer et al., 2012). HEV-
RNA can be detected in both serum and stool before the onset of clinical
symptoms and lasts less than a month after symptom onset in serum
but may persist longer in the stool (Krain et al., 2014). A severe form
of acute hepatitis (fulminant hepatic failure) has been observed in
patients with pre-existing liver diseases and in pregnant women
(Dalton et al., 2007; Navaneethan et al., 2008). The severity of HEV
infection in pregnant women may be associated with the hormonal
balance and immunologic complexity during pregnancy (Bose et al.,
2011; Navaneethan et al., 2008). HEV replication occurring in the
human placenta may lead to poor pregnant outcomes, including HEV
transmission from mother to newborn and abortion (Bose et al., 2014;
Navaneethan et al., 2008).
Chronic hepatitis E is deﬁned by the persistence of HEV-RNA and/or
anti-HEV IgM for more than six months with elevated alanine
aminotransferase (ALT) levels. Chronic HEV infection has been reported
primarily in immunocompromised individuals, in organ transplant
recipients, patients under chemotherapy, and HIV-infected patients
(Dalton et al., 2009; Kamar et al., 2008). Chronic hepatitis E has beenassociated with the development of ﬁbrosis and/or cirrhosis in patients
with solid-organ-transplantation (Kamar et al., 2008). Chronic HEV
infection largely depends on the host immune responses, and thus the
suppressed immunity in those speciﬁc groups of patients enables the
virus to persist and establish chronic infection. The impairment of
HEV-speciﬁc T-cell responses is likely associated with the development
of chronic hepatitis E (Suneetha et al., 2012). However, rare cases of
chronic and/or persistent HEV infection have also been reported in
healthy, immunocompetent individuals (Gonzalez Tallon et al., 2011).
HEV may also contribute to various extrahepatic manifestations,
including pancreatitis, hematological disorders (thrombocytopenia
and anemia), kidney disorders and neurological complications
(Guillain-Barré syndrome and meningoencephalitis) (Singh and
Gangappa, 2007; Thapa et al., 2009; Wedemeyer et al., 2012). The
discovery of HEV quasispecies in serum and cerebrospinal ﬂuid
additionally suggest a possible role in neurological disorders and relate
to the emergence of neurotropic HEV variants (Kamar et al., 2010). The
extrahepatic manifestation mechanism can be explained by HEV repli-
cation in the extrahepatic tissues/organs and cause local tissue damage
and inﬂammation. This is supported by recent ﬁndings, which showed
HEV replication in the human placenta and neuronal-derived tissues
(Bose et al., 2014; Drave et al., 2016). Other mechanisms such as
cross-reactive immune responses, generation of immune complexes,
and secondary infections have been proposed (Feng, 2016). However,
the exact underlying mechanism of extrahepatic manifestations by
HEV warrants further investigation.
3. HEV Biology and Molecular Virology
HEV is a small RNA, non-enveloped virus, 32–34 nm in diameter and
belonging to the genus Orthohepevirus of theHepeviridae family (Kamar
et al., 2012). The HEV genome is a positive-sense single-stranded RNA
molecule of 7.2 kb containing three open reading frames (ORF1, ORF2,
and ORF3), 5′- and 3′-untranslated regions (UTRs), and a polyA-tract
at the 3′-end (Kamar et al., 2012) (Fig. 1). ORF1 encodes the non-
structural proteins and enzymes including methyltransferase (MeT),
RNA helicase (Hel) and RNA-dependent RNA polymerase (RdRp)
required for RNA replication. ORF2 expresses the capsid protein. ORF3
overlaps partially with ORF2 and encodes a multifunctional phospho-
protein that can modulate cellular signaling and is related to particle
secretion (Parvez and Al-Dosari, 2015). A novel ORF4 of 158 amino
acids within ORF1 has been described recently for HEV-1. ORF4 is
involved in HEV replication by interacting with multiple viral proteins
(helicase, RdRp and X) and host factors such as eEF1α1 (eukaryotic
elongation factor 1 isoform-1) and β-tubulin (Nair et al., 2016). Howev-
er, the presence and functional role of ORF4 in other HEV genotypes
need to be explored. Additionally, two cis-reactive elements (CRE)
located at the junction (between ORF1 and ORF3) and at the 3′-end of
the ORF2 and 3′-UTR are essential for HEV replication and promoter
activity for the subgenomic viral RNA (Emerson et al., 2001).
Although the HEV life-cycle relates to other ssRNA viruses, it
warrants further investigation (Fig. 2). HEV attaches the cells via the
interaction of ORF2 with attachment receptors such as heparan sulfate
proteoglycans (HSPGs) and heat shock cognate protein 70 (HSC70)
and enters the cells throughdynamin-2, clathrin,membrane cholesterol
and actin dependent endocytosis (Holla et al., 2015; Kalia et al., 2009).
After entry, the virion uncoats and releases the viral RNA into the cyto-
plasm. The virus utilizes the host translation machinery to translate the
ORF1 polyproteins which include viral enzymes. The viral genomes are
replicated by the viral RNA helicase and RdRp, the ORF2 and ORF3
proteins are also translated from the viral subgenomic RNA (Debing et
al., 2016a). The replication complex of HEV is likely positioned at the
ER-Golgi intermediate compartment, where the viral proteins and
positive single-stranded RNA could be localized (Perttila et al., 2013;
Rehman et al., 2008). The assembly of RNA and ORF2 protein forms
the progeny viral particles, which are then released from the host cells
Fig. 1. Schematic description of the HEV genome and viral proteins. The ﬁgure shows linear, ssRNA (+) genome of ~7.2 kb HEV genome and corresponding viral proteins. The 5′-end is
capped and the 3′-terminus is polyadenylated. ORF1 encodes the nonstructural polyprotein, including methyltransferase (Met), Y-domain (Y), papain-like cysteine protease (PCP),
hypervariable region (HVR), macro-domain (X), RNA helicase (Hel) and RNA-dependent RNA polymerase (RdRp). ORF2 encodes the capsid protein (CP), containing S domain (S), M
domain (M) and P domain (P). The glycosylation sites of ORF2 are indicated (Asn137, Asn310, and Asn562). ORF3 encodes a small multifunctional protein (MFP) including
hydrophobic regions (D1, D2) and proline-rich regions (P1, P2). The phosphorylation site (Ser80) and the SH3-binding domain are indicated. ORF2 is translated by leaky scanning
from the bicistronic ORF3-2 ~2.0 kb subgenomic RNA. JR is ORF2 and ORF3 overlapping/intergenic-junction region; CRE is cis-reactive element; SP is signal peptide. Nucleotide
positions are relative to the HEV-1 Burmese strain (Acc. No. M73218)/HEV-3 47832 strain (Acc. No. KC618402). Asterisk (*) indicates the hot spot region for clinical mutations
(adapted from (Cao and Meng, 2012; Chandra et al., 2008b).
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(ESCRT) machinery. The interaction of the conserved PSAP motifs in
the viral ORF3 protein with the tumor susceptibility gene 101
(TSG101) (a component of the ESCRT machinery) is likely essential for
the maturation and egress of HEV (Nagashima et al., 2011a, 2011b)
(Fig. 2).
4. Genetic Variability of HEV and Clinical Implication
Seven HEV genotypes are recognized within the Orthohepevirus A
species based on the phylogeny of entire viral genomes (HEV-1 to
HEV-7) (Smith et al., 2016). Four HEV genotypes (HEV-1 to HEV-4)
are well recognized as human pathogens while HEV-5 and HEV-6 are
identiﬁed only in animals so far (wild boars) (Smith et al., 2014).
Recently, the camelid HEV-7 has been reported to infect human and
cause chronic hepatitis E, as observed in a liver transplanted patient
(Lee et al., 2016). The human pathogenic prototype strains include
HEV-1, HEV-2, HEV-3, HEV-4, and of HEV-7 (Kamar et al., 2012,
2014a; Meng, 2011). Four major human pathogenic HEV genotypes
have been further classiﬁed into 24 sub-genotypes including ﬁve HEV-
1 sub-genotypes (1a to 1e), two HEV-2 sub-genotypes (2a and 2b),
ten HEV-3 sub-genotypes (3a to 3j) and seven HEV-4 sub-genotypes
(4a to 4g) (Lu et al., 2006). However, the sub-classiﬁcation of HEV geno-
types is controversial, because of missing valid data and an inadequate
number of reference strains available for the various sub-genotypes.
The HEV genotypes have different reservoirs, and distinct distribu-
tion and transmission patterns. HEV-1 is frequently distributed in Asia,
HEV-2 in Africa and Mexico, HEV-7 in the Middle East, whereas HEV3
and HEV4 are distributed throughout the world (Kamar et al., 2012;
Lee et al., 2016; Rasche et al., 2016). HEV-1 andHEV-2 exclusively infect
humans, whereas HEV-3 and HEV-4 are more permissive with a wider
host range (especially swine, wild boar, rabbits, deer, and humans)
(Kamar et al., 2012, 2014a; Meng, 2011). HEV-7 can infect both camels
and humans (Lee et al., 2016). Zoonotic HEV has potential to cause fatal
disease in infected patients andmay becomemore transmissible among
humans (Aggarwal and Jameel, 2011). HEV-1 and HEV-2 are mainly
transmitted through the waterborne/fecal-oral route and are responsi-
ble for large waterborne outbreaks and epidemics in developing coun-
tries, whereas HEV-3, HEV-4 and HEV-7 are associated with zoonotic
transmission and cause sporadic infections in developed countries
(Kamar et al., 2012, 2014a; Lee et al., 2016; Meng, 2011).The HEV genotypes are believed to be associated with the clinical
course of the symptomatic infections. HEV-1 andHEV-2mainly contrib-
ute to severe acute hepatitis but not towards chronic HEV infection
(Aggarwal and Jameel, 2011; Krain et al., 2014). Infections with HEV-
3, HEV-4 and HEV-7 do not only cause acute hepatitis but can also
lead to chronic hepatitis in immunocompromised patients (Geng et
al., 2014; Geng et al., 2016; Lee et al., 2016; Rivero-Juarez et al., 2015).
Patients infected with HEV-4 had more severe outcomes compared to
those infected with HEV-3 (Mizuo et al., 2005). Infection with HEV-1
but not with HEV-3 and HEV-4 was associated with severe forms of
liver disease and complications in pregnant women (Krain et al.,
2014; Kumar et al., 2004). In addition, infection with HEV-3 has been
shown to cause fulminant liver failure in patients with pre-existing
liver diseases (Dalton et al., 2007; Peron et al., 2007). These data indicate
that HEV variability contributes signiﬁcantly to the pathogenesis and
severity of HEV infection.
HEV heterogeneity of the polyproline region (PPR) and macro
domain (X-domain) have been characterized in eight immunocompro-
mised patients with HEV persistence and six with resolving infections.
The diverse complexity of nucleotides and amino acids (aa) in both
the PPR and macro domain of ORF1 is higher in patients with chronic
HEV infections than those with resolving infections (Lhomme et al.,
2014a). Selection pressure of the host immune response during acute
infection may be a possible reason for this diverse complexity. This
suggests that the genetic heterogeneity enables the virus to better
adapt to the host and persist longer, and thus establish chronicity.
5. Recombination of HEV
Recombination events of HEV occurwithin seven deﬁnedHEV geno-
types and also between human and HEV strains (Smith et al., 2014).
Recombination events were frequently distributed in the X- and
helicase domains of ORF1 (Wang et al., 2010). Notably, HEV strain
with ORF1 rearrangement (derived from a chronically infected patient)
can efﬁciently adapt in cell culture (Johne et al., 2014). Insertion and
deletions were reported in the hypervariable domain (polyproline
region; HVR/PPR) of ORF1. A 171-nucleotide insertion encoding a 58
aa fragment of the human RPS17 gene (ribosomal protein S17)
(Shukla et al., 2011) and a 174 bp insertion of RPS17 (detected in a
chronically infected HEV patient) were associated with an increased
HEV replication in hepatoma cells (Kenney and Meng, 2015; Shukla et
Fig. 2. Effect of mutations on HEV replication cycle and clinical signiﬁcance. Schematic description of the HEV replication cycle and effect of mutations occurring in the HEV genome (red
boxes; domain and region are indicated) on the transcriptional/translational machinery (blue dotted box) of HEV. Asterisks (***) indicate mutations described in the text. The possible
effect of mutations on HEV replication is denoted at the side, described clinical outcome below the red boxes.
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immunocompromised patients with HEV persistence and 32 with
resolving infections. Of the 27 strains isolated from patients with HEV
persistence, the recombination occurred in three HEV strains over the
infection period (Lhomme et al., 2014b). Recombination events increase
the likelihood of genetic variability and thus diverse pathogenesis with
a prospective potential for chroniﬁcation of HEV infection (Nguyen et
al., 2012). In addition, two fragments of human origin (inter-α-trypsin
inhibitor-ITI, and tyrosine aminotransferase-TAT) were found to be
inserted in the PPR. Those inserted fragments enhanced the HEV
replication, probably by providing a new potential regulatory site
(Lhomme et al., 2014b).
6. HEV Mutations and Their Functional Role
RNA viruses exhibit high genetic variability by rapid evolution with
estimated mutation rate ranging from 10−6 to 10−4 substitutions per
nucleotide per strand copying (Sanjuan et al., 2010). The HEV mutation
rates were estimated indirectly from clinical isolates as 1.5 base substi-
tutions per site per year andwere similar to those reported for hepatitis
C viruses (Takahashi et al., 2004). Mutations can occur frequently over
the entire HEV genome during propagation and consecutive passages
for adaptation to cell culture (Lorenzo et al., 2008). High variabilityand frequent selection of mutations in the HEV genome is due to the
transcription process. The viral RdRp, which lacks the proof-reading
ability of DNA polymerases, likely increases the variations in the HEV
genome. On the other hand, the selection pressure imposed by antiviral
drugs and host immune responses may additionally contribute to in-
creasedHEV variability (Lhomme et al., 2014a). Although a quasispecies
is linked to mutations, not all mutations in the viral genome shall
generate viable virus quasispecies (Lauring and Andino, 2010).6.1. Mutations in the ORF1 Region
ORF1 encodes several non-structural proteins required for HEV
replication and protein processing including MeT, papain-like cysteine
protease (PCP), Hel, and PdRp activities (Fig. 1). ORF1 also contains sev-
eral functional domains namely the Y-domain, HVR and macro domain
(X-domain), which show homologies to other positive-stranded RNA
viruses (Cao and Meng, 2012; Koonin et al., 1992). MeT is responsible
for capping the 5′-end of the viral pregenomic RNA, which is critical
for viral infection (Emerson et al., 2001). In the capping process, Hel is
involved in phosphatase activity that catalyzes the initial cap formation.
The Hel-domain also possesses RNA duplex unwinding activities (Karpe
and Lole, 2010a, 2010b).
35H. van Tong et al. / EBioMedicine 11 (2016) 31–42Although the PCP has been predicted within the ORF1 polyprotein
by a computer-assisted analysis (Koonin et al., 1992), the function of
the protease activity is unclear. By constructing a series of HEV replicons
harboring numerous mutations in the PCP region and followed by in
vitro analyses, nine aa substitutions (H443L, C457A, C459A, C471A,
C472A, C481A, C483A, H497L and H590L) were associated with com-
plete suppression of HEV replication (Parvez, 2013). A catalytic dyad
(C434–H443) and bivalent metal-binding motifs (C457–H458–C459
and C481–C483) were essential for HEV protease structural-integrity
(Parvez and Khan, 2014). These results indicate that protease activity
is essential for HEV replication and mutations in the PCP region may
affect HEV protease activity by modifying the enzyme structure
(Table 1).
The HVR domain overlaps PPR between the PCP and X-domain
(Macro-D) and contributes to viral replication efﬁciency and adaptation
(Pudupakam et al., 2009, 2011; Purdy et al., 2012). HVR varies in length
among HEV strains and genotypes, shows sequence heterogeneities,
and can tolerate small deletions and insertions (Pudupakam et al.,
2009). The variation in length of the HVR domain is associated with
HEV attenuation (Pudupakam et al., 2009). Consistently, the deletions
in the N-terminal and central regions of the HVR domain have signiﬁ-
cant effect while deletion in the C-terminal region has a relatively lesser
impact on the replication efﬁciency. Furthermore, complete HVR
deletion of the avian HEV eliminates virus infectivity, but not viral
replication in vivo (Pudupakam et al., 2011). These ﬁndings indicate
that the HVR domain is not essential for viral replication, but has a
role in HEV infectivity. The HVR domain may involve virus entry and
assembly by interacting with other viral and host factors. A 282 bp-
insertion (duplicated 258 bp HVR-derived and 24 bp RdRp-derived
fragments) in the HVR domain of an isolate from patient with chronic
hepatitis E was associated with increased viral replication. Particularly,
the 24 bp RdRp-derived insertion contributed to viral replication
(Debing et al., 2016b). Therefore, the deletion/insertion or recombina-
tion events occurring in HVRmay be associated with HEV pathogenesis
and thus clinical outcome.
The X-domain is involved in ADP-ribose metabolism and posttrans-
lational modiﬁcations and is homologous to other pathogens (Holla et
al., 2013). However, X-domain function in HEV physiology is poorly
characterized. Themacro domain could recruit poly (ADP-ribose)-mod-
iﬁed cellular factors and might have an impact on HEV replication
(Egloff et al., 2006). A highly conserved ‘glycine-triad’ comprised of
three aa substitutions G815V, G816V and G817V in the downstream
X-domainwas identiﬁed and two of those (G816V and G817V) resulted
in the complete suppression of HEV replication (Parvez, 2013). Six HEV
replicons harboring the aa substitutions N806A, N809A, H812L, G815A,
G816A and G817A were constructed to characterize the functional role
of the X-domain. The results revealed that themutationsN809A, H812L,
G816A/V andG817A/V lead to a complete abrogation of HEV replication
(Parvez, 2015a). These ﬁndings indicate the critical role of X-domain in
regulation of HEV physiology and mutations in this domain completely
damage HEV replication (Table 1).
Viral helicase activity is critical for HEV replication and speciﬁc
mutations in the Hel region can stop helicase activity (Karpe and
Lole, 2010a, 2010b). The amino acid substitutions in the Hel domain
(L1110F and V1120I) are frequently detected in HEV-1 isolates
derived from patients with fulminant hepatic failure (Devhare et
al., 2014). These distinct mutants were shown to inﬂuence ATPase
activity but not the RNA duplex unwinding activity of the helicase
enzyme. Notably, HEV mutant replicons with the single mutation
(L1110F or V1120I) and the double mutation (L1110F/V1120I)
showed a signiﬁcant decrease in viral replication in comparison to
wild-type HEV (Devhare et al., 2014). In addition, artiﬁcial deletions
in the Hel domain (motifs Ia and III) signiﬁcantly impaired ATPase
and unwinding activities of the helicase enzyme (Mhaindarkar et
al., 2014). These ﬁndings indicate that the negative regulation of
helicase activity by these non-synonymous substitutions (L1110For V1120I) and deletions (motifs Ia and III) in the Hel domain are
associated with reduced HEV replication (Table 1).
The RdRp domain contains eight conserved motifs that are closely
homologous to RdRps of other positive-stranded RNA viruses such as
hepatitis C virus (Agrawal et al., 2001). The RdRp replicates the HEV ge-
nome through an anti-genomic RNA intermediate and the RdRp activity
could be localized to the endoplasmic reticulum (Rehman et al., 2008).
Several HEV mutations namely Y1320H, K1383N, D1384G, K1398R,
V1479I, Y1587F and G1634R have been identiﬁed in patient-derived
HEV isolates. These mutations were demonstrated in vitro to associate
with HEV replication ﬁtness (Debing et al., 2014, 2016b; Todt et al.,
2016). The ﬁndings indicate that the mutations occurring in the RdRp
domain can affect the HEV replication by modulating the RdRp activity
(Table 1).
6.2. Mutations in the ORF2 Region
ORF2 encodes the viral capsid protein, which assembles after glyco-
sylation and encapsidation of the viral genomic RNA into the infectious
viral particles (Jameel et al., 1996). The capsid protein is immunogenic
since neutralizing antibodies effectively target conformational epitopes
at the P-domain (Zhou et al., 2005) (Fig. 1). Besides structural proper-
ties, HEV capsid protein is involved in host cell interaction by a potential
ER localization signal (Jameel et al., 1996). ORF2 contributes to virus-
host interaction as ORF2 revealed modulatory effects on eIF2a, ATF-4,
Hsp72, NFkB, and activation of the CHOP promoter (John et al., 2011;
Surjit et al., 2012). Interactions of capsid proteins with host factors
(Grp78/BiP, α-tubulin, and Hsp90) are necessary for virus attachment,
uptake, and trafﬁcking (Zheng et al., 2010). The C-terminal 52 aa
(C52aa) domain of the capsid protein is required to promote accurate
encapsidation and stabilize encapsidated viral particles (Shiota et al.,
2013).
Three mutations (T5338C, A5362G, and C6356T) resulted in aa
changes (F51L, T59A, and S390L, respectively) and a deleterious point
mutation A756 resulted in a downstream frame-shift of the ORF1 gene
have been identiﬁed in ORF2 (Huang et al., 2005). These mutations
occur naturally under selective immune pressure and may inﬂuence
the viral protein function thus contribute to a decreasedHEV replication
and infectivity (Huang et al., 2005). Although ORF2 production was not
signiﬁcantly affected by these mutations (F51L, T59A, and S390L), the
F51L mutation partially contributed to virus attenuation and the T59A
and S390L mutations resulted in a more drastic HEV attenuation
(Cordoba et al., 2011). In this regard, the F51L and T59A mutations
may affect viral genomic RNA packaging, and the S390L mutation
may prevent the interaction between virus and host cell receptor by
changing the structure of antigenic epitopes (Cordoba et al., 2011).
The non-synonymous substitutions at aa-positions 137, 310 and 311
(especially Asn to Gln) prevent glycosylation of corresponding sites in
the glycosylation motif of HEV capsid protein. These mutations do
not signiﬁcantly affect either the viral replication or capsid protein
synthesis. However, they eliminate HEV infectivity by preventing the
formation of HEV particles. Although the mutation N562Q does not
stop HEV morphogenesis, it rather affects the dimerization of the
ORF2 protein and the infectivity of the newly synthesized HEV particles
(Graff et al., 2008). The substitutions N562Q/D/P/Ywere further veriﬁed
to evolve in glycosylation, dimerization and especially in the activity of
neutralizing epitopes of the capsid protein (Xu et al., 2016). Recently
described substitutions in ORF2 L477T and L613T (HEV-4) and V606A
(HEV-1) were associated with HEV immunoreactivity by affecting the
neutralization epitope (Liang et al., 2010; Zhang et al., 2008). These
ﬁndings indicate that the ORF2 protein structure is critical for HEV
replication, infectivity, and immunoreactivity (Table 1). The ORF2
non-synonymous substitutions resulting in an alteration of epitope
structure may facilitate HEV to adapt and/or escape successfully the
host immune response, which can lead to chronicity (Todt et al.,
2016). Under host immune pressure, HEV mutations in ORF2 may
Table 1
Artiﬁcial HEV mutations and their functional signiﬁcance in the physiological activity and infectivity.
Substitution/mutation Amino acid change Domain/region HEV genotype Functional signiﬁcance References
NA H443L; C457A; C459A; C471A; C472A;
C481A; C483A; H497L; H590L
PCP/OFR1 HEV-1 Completely abolish HEV replication by modifying the enzyme
structure
Parvez (2013); Parvez and Khan
(2014)
Insertion/deletion NA HVR/ORF1 Human HEV-1 avian HEV
swine HEV-3
Associated with HEV attenuation Pudupakam et al. (2009)
Complete deletion NA HVR/ORF1 avian HEV human HEV Abolish HEV infectivity but not inﬂuence HEV replication Pudupakam et al. (2011)
Insertion/deletion of a 24 bp
RdRp-derived fragment
NA HVR/ORF1 human HEV-3 Decrease HEV replication Debing et al. (2016b)
NA N809A; H812L; G816A/V; G817A/V X/OFR1 HEV-1 Completely abolish HEV replication Parvez (2013); Parvez (2015a)
NA L1110F; V1120I Hel/ORF1 Human HEV-1 Decrease HEV replication by affecting the ATPase activity but not the
RNA duplex unwinding activity of helicase enzyme
Devhare et al. (2014)
Deletion NA Hel/ORF1 NA Decrease HEV replication impairing the ATPase and unwinding
activities of helicase enzyme
Mhaindarkar et al. (2014)
NA K1383N RdRp/ORF1 HEV-3 Reduces viral replication and increases ribavirin sensitivity Debing et al. (2016b)
NA Y1320H; G1634R/K RdRp/ORF1 HEV-1, HEV-3 Increased efﬁciency of viral replication and infectivity Debing et al. (2016b); Debing et al.
(2014); Todt et al., 2016
T5338C F51L ORF2 Swine HEV Decrease HEV replication and infectivity by affecting viral genomic
RNA packaging
Peron et al. (2016); Perttila et al.
(2013)
A5362G T59A ORF2 Swine HEV Decrease HEV replication and infectivity by affecting viral genomic
RNA packaging
Huang et al. (2005); Cordoba et al.
(2011)
C6356T S390L ORF2 Swine HEV Decrease HEV replication and infectivity by preventing host virus
interaction
Peron et al. (2016); Perttila et al.
(2013)
NA N137Q; N310Q; N311Q ORF2 NA Prevent glycosylation of capsid protein and formation of HEV
particles
Graff et al. (2008)
NA N562Q/D/P/Y ORF2 NA Affect the dimerization of ORF2 protein and HEV infectivity Graff et al. (2008)
NA L477T; L613T ORF2 HEV-4 Inﬂuence immunoreactivity of HEV by affecting the neutralization
epitope
Zhang et al. (2008); Liang et al.
(2010)NA V606A ORF2 HEV-1
A5145C; A5178C; A5190C; G5676T;
T5690G
NA ORF2–ORF3 HEV-2 Abolish the ORF2 production (but not ORF3) Graff et al. (2005a)
CGC5148–5150AGA NA ORF2–ORF3 HEV-2 Abolish ORF3 production (but not ORF2) Graff et al. (2005a)
A5108Δ; T5109C; C5112U;
TCT5116–5118AGC; T5121C
NA ORF2–ORF3 HEV-2 Abolish both production of both ORF2 and ORF3 Graff et al. (2005a)
NA S80A (V66G) ORF3 (ORF2) NA May affect the regulatory role of ORF3 protein in HEV assembly,
inﬂuence ORF2–ORF3 interaction
Tyagi et al. (2002); Graff et al.
(2005a)
G5101U; U5100C; C5117G; U5118G NA CRE/ORF3 HEV-2 Affect HEV replication and infectivity by modifying the CRE structure Parvez (2015b)
G6574C; C6570G; G7106T/A; G7097A;
C7144A
NA CRE/ORF2 HEV-3 Affect HEV replication and infectivity by modifying the CRE structure Emerson et al. (2001); Emerson et al.
(2013); Graff et al. (2005b)
NA: not applicable.
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outcomes and progression of liver disease (Suneetha et al., 2012).
6.3. Mutations in the ORF3 Region
The ORF3 encodes a small phosphoprotein of 114 amino acids (HEV-
1, -2 and -4) or 113 amino acids (HEV-3) that is translated from the
2.2 kb sgRNA. ORF3 is essential to promote cell survival and prolifera-
tion, modulation of the immune responses in the acute phase, and in
immune-suppression (Cao and Meng, 2012). The ORF3 protein is
required for regulation of HEV replication and infectivity and is a multi-
functional, pleiotropic protein, and interacts with host cellular signaling
(Chandra et al., 2008a; Moin et al., 2009). Therefore, ORF3 expression
may have a pivotal effect on HEV pathogenicity. ORF3 interacts with
ORF2 in a phosphorylation-dependent manner and the 25-aa region
(residues 57–81), especially the phosphorylation at the position S80 of
ORF3, is responsible for the ORF2–ORF3 interaction (Tyagi et al.,
2002). The mutation S80A (but not S80L, which does not change aa in
ORF2) is associated with abolishment of HEV infectivity. However,
ORF3 phosphorylation at position S80 is not required for viral replica-
tion and infectivity (Graff et al., 2005a). Due to the overlapping of
ORF2 and ORF3, the ORF3 S80A mutation also corresponds to the
V66G aa substitution in ORF2 (Graff et al., 2005a). The S80A mutation
thereforemay affect the ORF3 regulation duringHEV assembly by either
an unknown mechanism or by inﬂuencing the ORF2–ORF3 interaction
through modifying the structure of both ORF2 and ORF3. In addition,
two conserved PSAP motifs have been identiﬁed to residues aa 86–89
and aa 95–98 of ORF3. Mutations in these motifs were associated with
decreased HEV replication (Nagashima et al., 2011a) (Table 1).
Mutations in the ORF3 and ORF2–ORF3 overlapping regions are
associated with the production of ORF2 and ORF3 proteins (Graff et
al., 2005a). The mutations A5145C, A5178C, A5190C, G5676T and
T5690G stop the ORF2 expression (but not ORF3) while the mutation
CGC5148–5150AGA eliminates ORF3 production (but not ORF2). The
mutations A5108Δ, T5109C, C5112U, TCT5116–5118AGC and T5121C
damage the expression of both ORF2 and ORF3. These mutations
eliminating ORF3 production are associated with HEV infectivity in an
animal model system (Graff et al., 2005a) (Table 1). Furthermore, the
interaction of ORF3 protein with various host factors deactivates the
ORF3 protein function thatmay subsequently eliminate viral replication
and infectivity (Moin et al., 2007, 2009). The highly dynamic activity of
ORF3 protein in interaction with host factors may lead to stimulation
and enhancement of the host immune response that enables the host
to clear the virus more rapidly. This may provide an explanation for
the self-limitation and a short period of HEV persistence during clinical
course. In addition, mutations in the ORF3 protein may modulate its
binding capacity to the host proteins that results in a complexity of
immune response and clinical outcomes. However, more studies are
required to clarify this hypothesis.
6.4. Mutations in the Junction and cis-Reactive Elements (CRE)
The junction region located between the end of ORF1 and beginning
of ORF3 was predicted to contain a highly conserved stem-loop (SL)
structure (Cao et al., 2010) (Fig. 1). A point mutation at the third in-
frame AUG in the junction region, which is the exact start position for
ORF3 translation, completely stops virus infectivity (Huang et al.,
2007). An increased number of mutations in the loop, especially at the
AGA motif, is associated with reduced HEV replication, and mutation
on the stem of the sub-genome start sequence leads to an inhibition of
HEV replication (Cao et al., 2010). The sequence and structure of the
junction region play an important role in HEV replication while muta-
tions occurring at the third in-frame AUG in the junction region may
inhibit the ORF3 production. However, the precise mechanism of how
the junction region inﬂuences the HEV replication is unclear.Two CREs have been identiﬁed in HEV; the ﬁrst CRE is located at the
3′-end of ORF2 (Emerson et al., 2001) and the second CRE is located in
the ORF1–ORF3 intergenic junction region of the HEV genome, which
may be essential for HEV replication and important for ORF2 and
ORF3 expressions (Graff et al., 2005a) (Fig. 1). The mutations identiﬁed
in the ﬁrst CRE (G5101U, U5100C, C5117G, U5118G), which form the
“lower-stem” structure of CRE, affect HEV replication and are associated
with reducedHEV infectivity (Parvez, 2015b). A functional RNA element
with two highly conserved stem-loop structures (ISL1 and ISL2) within
ORF2 and 19 silent mutations were identiﬁed to disrupt the stem-loop
structures and abolish capsid protein synthesis (Emerson et al., 2013).
The mutations G6574C, C6570G, G7106T/A, G7097A and C7144A are
also associated with HEV attenuation by disrupting the predicted
stem-loop structures of HEV-RNA molecule (Emerson et al., 2001,
2013; Graff et al., 2005b) (Table 1).
7. HEV Mutations and Clinical Relevance
An in-frame deletion of 246 bp in ORF3 of Indian HEV strain isolated
from clinical samples has been reported, however, the functional and
clinical relevance of this deletion were unknown (Ray et al., 1992). An
analysis of 22HEV-4 full-length sequences frompatientswith fulminant
and acute hepatitis found that the substitutions at the positions C1816
and U3148 were signiﬁcantly associated with fulminant hepatitis
(Inoue et al., 2006). However, only the mutation U3148 was conﬁrmed
to be associated with fulminant hepatitis by an additional analysis of 16
HEV-4 isolates. Further analysis of 86 HEV isolates showed that the
U3148 variant revealed a stronger association with fulminant hepatitis
in comparison to other variants (C3148 or G3148), and was associated
with lower prothrombin activity (Inoue et al., 2006). A comparable
study extended the results using 28 HEV-4 full-length sequences
(from fulminant and acute hepatitis) and identiﬁed the C5907 variant
most signiﬁcantly associated with fulminant hepatitis (Inoue et al.,
2009). An additive effect of both U3148 and C5907 mutations on fulmi-
nant hepatitis development was conﬁrmed by further analysis of full-
length sequences of 28HEV-4 and 11HEV-3 isolates aswell as 35 partial
sequences (Inoue et al., 2009). However, the mechanism of how U3148
and C5907mutations inﬂuence hepatitis E progression is unresolved as
these mutations are silent substitutions not changing the aa (Table 2).
The ORF1 mutation V1213A corresponding to the aa substitution
V239A in the Hel domain was found in all patients with more severe
hepatitis but not in the patient with mild clinical course indicating
that the V239A mutation can be associated with increased virulence
(Takahashi et al., 2009). Notably, the V239A substitution in the Hel
domain may enhance helicase activity and subsequently increase HEV
replication (Ahola et al., 2000). Six aa changes in HEV-1 ORF1 including
T563C (aa F179S), G977A (A317T), C2232T (T735I), T3355C (L1110F),
G3386A (V1120I), and T4344A (F1439Y), were identiﬁed to be signiﬁ-
cantly associated with fulminant hepatic failure (Mishra et al., 2013).
A total of 22 nucleotide substitutionswere identiﬁed in the ORF1 region
of 55 HEV sequences obtained from patients with acute viral hepatitis
and those with acute liver failure. Most of these mutations including
two non-synonymous substitutions C4476G (C1483W) and A4616C
(N1530T) in the RdRp were found only in the HEV sequences from
acute liver failure patients (Borkakoti et al., 2016). The mutations
C1483W and N1530T were signiﬁcantly associated with high viral
load, abnormal prothrombin time, high bilirubin, and high mortality
(Borkakoti et al., 2016). The association of HEV mutations in ORF2
with disease severity was investigated. Six substitutions including
C5927T, C5933T, T6014C, C6032T, G6098A, C6104T, and a novel amino
acid mutation P259S in ORF2 were identiﬁed to be signiﬁcantly
associatedwith fulminant liver failure (Borkakoti et al., 2014). These re-
sults indicate that non-synonymous substitutions can be associated
with virulence and may affect viral replication (mutations in the
RdRp) and especially enhance host immune response via modifying
the antigen epitopes (non-silent mutations in ORF2 region) (Table 2).
Table 2
HEV mutations detected in patient-derived isolates and their clinical relevance.
Nucleotide substitution Amino acid change Domain/region HEV genotype Associated clinical manifestation Mechanism Reference
C1816 no ORF1 Clinical isolates HEV-4 Fulminant hepatitis failure Unknown Inoue et al. (2006); Inoue et al. (2009)
U3148 no ORF1
C5907 no ORF2
186 bp insertion no HVR/ORF1 Clinical isolates HEV-3 Chronic hepatitis Unknown Johne et al. (2014)
90 bp insertion no HVR/ORF1 Clinical isolates HEV-3 Unknown Unknown Legrand-Abravanel et al. (2009)
171 bp insertion no HVR/ORF1 Clinical isolates HEV-3 Chronic hepatitis Efﬁcient growth in cell culture Shukla et al. (2011)
174 bp insertion no HVR/ORF1 Clinical isolates HEV-3 Chronic hepatitis Cross-species infections Shukla et al. (2011)
117 bp insertion no HVR/ORF1 Clinical isolates HEV-3 Chronic hepatitis Growth advantage in cell culture Nguyen et al. (2012)
a 282 bp-insertion no HVR/ORF1 Clinical isolates HEV-3 Ribavirin treatment failure Unknown Debing et al. (2016b)
NA V239A Hel/ORF1 HEV-3 More severe hepatitis Enhance the helicase activity Takahashi et al. (2009)
T563C F179S MeT/ORF1 Clinical isolates HEV-1 Fulminant hepatic failure Unknown Mishra et al. (2013)
G977A A317T Y/ORF1
C2232T T735I HVR/ORF1
T3355C L1110F Hel/ORF1
G3386A V1120I Hel/ORF1
T4344A F1439Y RdRp/ORF1
C4476G; A4616C C1483W; N1530T RdRp/ORF1 Clinical isolates HEV-1 Fulminant hepatic failure Maybe enhance HEV replication? Borkakoti et al. (2016)
C5927T NA ORF2 Clinical isolates HEV-1 Fulminant hepatic failure Unknown Borkakoti et al. (2014)
C5933T NA ORF2
T6014C NA ORF2
C6032T NA ORF2
G6098A NA ORF2
C6104T NA ORF2
NA P259S ORF2
NA Y1320H; G1634R/K RdRp/ORF1 Clinical isolates HEV-3 Ribavirin treatment failure Increased efﬁciency of viral replication and infectivity Debing et al. (2016b); Debing et al. (2014);
Todt et al. (2016)
NA K1383N RdRp/ORF1 Clinical isolates HEV-3 Ribavirin treatment failure Unknown Debing et al. (2016b); Todt et al. (2016)
NA D1384G; K1398R; V1479I; Y1587F RdRp/ORF1 Clinical isolates HEV-3 Ribavirin treatment failure Unknown Todt et al. (2016)
246 bp deletion NA ORF3 Clinical strain Unknown Unknown Ray et al. (1992)
NA: not applicable.
38
H
.van
Tong
etal./EBioM
edicine
11
(2016)
31–42
39H. van Tong et al. / EBioMedicine 11 (2016) 31–42The abundance of mutations in the HEV genome from patient isolates is
probably due to selective immune pressure. Thesemutations enable the
virus to better adapt andmodulate the host immune responses that lead
to severity of complications.
8. HEV Mutations and Vaccination
Prevention of HEV infection in endemic areas is based on the
implementation of appropriate hygiene and sanitary measures to
avoid fecal-oral transmission. In regions where HEV infection is sporad-
ic, the consumption of raw food should be avoided. HEV infection can be
prevented with effective HEV vaccines and ORF2 is widely used as a
target for vaccine development (Zhang et al., 2015). Mutations in
ORF2 may lead to a failure of an adaptive cellular immune response in
vaccinated individuals. Therefore, mutations occurring in ORF2 sensi-
tively affecting the ORF2 protein structure is one of the challenges for
the protective efﬁciency of HEV vaccine programs. On the other hand,
a number of mutations resulting in HEV attenuation (e.g., F51L, T59A,
S390L, N562Q/D/P/Y, L477T, L613T and HVR deletion) may provide a
basis for the development of live-attenuated vaccines against HEV
(Cordoba et al., 2011; Pudupakam et al., 2009; Zhang et al., 2008). A
strategy for viral attenuation and vaccine development has been
proposed based on mutating the conserved active site lysine residue
to arginine of the viral RdRp (Weeks et al., 2012). Therefore, HEV
mutations in the RdRp domain and deletions in the HVR domain have
repercussions for the development of live, attenuated HEV vaccines.
9. Clinical Relevance of HEV Mutations in Antiviral Therapy
Although no HEV-speciﬁc treatment options show signiﬁcant antivi-
ral activity, the effectiveness of PEG-interferon-α in combination with
ribavirin, and ribavirin alone for HEV infection have been recently
documented (Kamar et al., 2014b; Peron et al., 2016; Wedemeyer et
al., 2012). However, ribavirin treatment failure was reported in patients
with chronic hepatitis E (Debing et al., 2014, 2016b; Gisa et al., 2015;
Lhomme et al., 2015; Todt et al., 2016) (Table 2). The entire HEV
sequences before, during and after treatment courses were compared
and a nucleotide substitution (G N A) resulting in a G1634R mutation
in the C-terminal region of the HEV-3 RdRp was identiﬁed (Debing et
al., 2014). Although showing no effect on ribavirin resistance, the vari-
ants 1634R and 1634K signiﬁcantly contribute to an increased efﬁciency
of viral replication and infectivity compared to the wild-type G1634
(Debing et al., 2014). Comparable results conﬁrmed a similar role for
HEV-1 (Debing et al., 2014). This result was further supported by a
clinical observation that plasma HEV-RNA levels were signiﬁcantly
increased in patients infected with 1634R mutant compared to non-
1634R mutant viruses (Lhomme et al., 2015). These ﬁndings suggest
that G1634R/K may not be a direct antiviral resistance mutation but
partially involved in ribavirin treatment failure by enhancing HEV
replication. By analyzing 63 HEV sequences from solid-organ transplant
patients with chronic hepatitis E, the prevalence of the G1634R
mutation was shown to be higher in non-sustained virologic response
(SVR) compared to SVR patients (Lhomme et al., 2015). This observa-
tion is supported by evidence that the proportion of the G1634R
mutation was rapidly increasing in patients with ribavirin treatment
failure (Parvez, 2013; Xu et al., 2016). Antiviral resistance mutations
(G1634R/K) can occur in HEV genome under ribavirin treatment, since
ribavirin has been recently demonstrated to cause mutations in the
HEV genome as well as in other RNA viruses (Debing et al., 2016b).
Ribavirin therapy can lead to an increased HEV variability (ORF1, ORF2
and ORF3) over time, especially in the RdRp domain (Todt et al.,
2016). However, the presence of the 1634R mutation neither leads to
absolute ribavirin resistance nor inﬂuences the response to re-treat-
ment with ribavirin (Galante et al., 2015; Lhomme et al., 2015). This re-
sult is in line with a ﬁnding showing that the ribavirin treatment failure
is not directly caused by the G1634R mutation (Debing et al., 2014).Besides the described G1634R mutation, two other substitutions
(Y1320H, K1383N) in the RdRp domain, as well as two mutations
(A723V, A647T) and a 282 bp-insertion (a duplicated 258 bp HVR-
derived and a 24 bp RdRp-derived fragments) in the HVR were identi-
ﬁed. Notably, the frequency of these substitutions (Y1320H, K1383N,
G1634R and A723V) increased during the course of ribavirin treatment
(Debing et al., 2016b). The G1634R and Y1320H mutations enhanced
viral replication but did not affect ribavirin susceptibility, whereas the
K1383N mutation abrogated viral replication and was associated with
increased ribavirin sensitivity by affecting the binding activity of the
RdRp domain to guanosine-5′-triphosphate (GTP) (Debing et al.,
2016b). Although Y1320H andG1634R/K can compensate for the harm-
ful effect on viral replication caused by the K1383Nmutation (Debing et
al., 2016b), the interaction among these mutations and their functional
role is yet to be understood. The A723V mutation had no effect on viral
replication whereas the 282 bp-insertion in the HVR signiﬁcantly in-
creases viral replication. However, the artiﬁcial insertion and deletion
of the 24 bp RdRp-derived fragment reduced viral replication compared
to wild-type HEV, suggesting a role of the insertion and also other
unknown factors (Debing et al., 2016b). In addition, four additional
substitutions (D1384G, K1398R, V1479I and Y1587F) together with
the known mutations K1383N and G1634R in ORF1 were identiﬁed. Of
those, themutation G1634R could be detected in low frequencies before
ribavirin therapy (Todt et al., 2016). These additional mutations
(D1384G, K1398R, V1479I and Y1587F) were associated with increased
ribavirin sensitivity, andwith higher HEV replication (Todt et al., 2016).
The recentﬁndings clearly demonstrate themutagenic effect of riba-
virin on the HEV genome, which can lead to an emergence of distinct
viral populations (Debing et al., 2014, 2016b; Gisa et al., 2015; Todt et
al., 2016). These distinct viral populations resulted from ribavirin
treatment failure may cause a more complicated clinical outcome,
extrahepatic manifestations and may have different transmission
patterns. Development of a new antiviral therapy or/and combination
with an alternative therapeutic option (eg. PegIFNα, Sofosbuvir) may
help to increase the efﬁciency of treatment course and to reduce the
treatment failure risk as well as to avoid the emergence of the viral
populations associated with drug resistance and fulminant liver failure.
Investigating potential HEV mutations related to resistance to new
antiviral therapies are recommended. In clinical practice, systematic ex-
amination of HEV genome variants by next-generation sequencing
should be considered for any clinical relevance, which may associate
with treatment failure, chronic and fulminant infections to predict
therapy outcomes and in the progression of liver diseases.
10. Conclusions and Perspectives
Although HEV infection is largely controlled by host immune
responses, viral factors including HEV genetic variability associate
with the clinical course, host adaption, and antiviral resistances.
Different HEV genotypes exhibit a selective host range with unique
transmission patterns and pathogenesis. Deletion/insertion, recombina-
tion and substitutions occurring in the HEV genome can inﬂuence HEV
replication and virus-host interaction, and be subsequently associated
to pathogenesis (Table 1 and Fig. 2). Under host immune pressure,
clinically relevant non-synonymous and silent mutations occurring
throughout the entire HEV genome may be associated with severe
forms of the disease and potentially anti-viral resistances (Table 2 and
Fig. 2). Ribavirin treatment failure is associated with the RdRp
mutations Y1320H, K1383N, D1384G, K1398R, V1479I, Y1587F and
G1634R. The mutations Y1320H and G1634R contribute to decreased
susceptibility to antiviral drugs by enhancing HEV replication and
infectivity, whereas the other mutations (eg. K1383N) likely reduce
viral replication and increases ribavirin sensitivity. These mutations
may affect the efﬁciency of viral RdRp activity; however, the precise
role of these identiﬁed mutations remains unclear. Except for the drug
resistance-related HEV mutations in the RdRp domain, most mutations
40 H. van Tong et al. / EBioMedicine 11 (2016) 31–42in other regions found in clinical isolates do not corroboratewith results
from artiﬁcial mutations in functional studies, thus suggesting the
nature of mutational complexity. Further studies will help to elucidate
the possible contribution of HEV variants in HEV physiology, pathogen-
esis and clinical relevance.
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